Candesartan-SZ, tablets 16 mg 30 pcs

An antihypertensive agent, angiotensin II receptor antagonist. It blocks AT1-receptors, which leads to reduction of biological effects of angiotensin II (mediated by this type of receptors), including vasoconstrictor effect, stimulating effect on aldosterone release, regulation of salt and water homeostasis and stimulation of cell growth.

The antihypertensive effect is caused by lowering PPS without reflex elevation of HR.

It does not inhibit ACE. Does not interact with or block other hormone receptors or ion channels important to the regulation of cardiovascular function.

Indications

Arterial hypertension.

Pharmacological effect

Antihypertensive agent, angiotensin II receptor antagonist. Blocks AT1 receptors, which leads to a decrease in the biological effects of angiotensin II (mediated by receptors of this type), incl. vasoconstrictor effect, stimulating effect on the release of aldosterone, regulation of salt and water homeostasis and stimulation of cell growth.

The antihypertensive effect is due to a decrease in peripheral vascular resistance without a reflex increase in heart rate.

Does not inhibit ACE. Does not interact with or block other hormone receptors or ion channels that are important for regulating the functions of the cardiovascular system.

Special instructions

It is not recommended for use in patients with severe renal failure (creatinine clearance less than 15 ml/min), with primary hyperaldosteronism.

Before starting treatment with candesartan, correction of water and electrolyte imbalances should be carried out.

When used in patients with renal failure, plasma potassium and creatinine levels should be periodically monitored.

Use with caution in patients with hemodynamic disorders caused by aortic or mitral stenosis, with obstructive hypertrophic cardiomyopathy.

It should be borne in mind that in patients with ischemic cardiopathy and ischemic cerebrovascular diseases, severe arterial hypotension can lead to the development of myocardial infarction or stroke.

Impact on the ability to drive vehicles and operate machinery

If it is necessary to use it in patients engaged in potentially hazardous activities (including driving), it should be kept in mind that candesartan can cause dizziness and weakness.

Active ingredient

Candesartan

Composition

Active substance:
candesartan cilexetil 16 mg;
Excipients:
lactose monohydrate, microcrystalline cellulose, pregelatinized starch, croscarmellose sodium, povidone, colloidal silicon dioxide, sodium stearyl fumarate.

Contraindications

Severe liver failure and/or cholestasis, pregnancy, lactation (breastfeeding), hypersensitivity to candesartan.

Side Effects

From the side of the central nervous system: dizziness.

From the respiratory system: cough, flu-like symptoms, rhinitis, pharyngitis, increased incidence of respiratory infections.

From the digestive system: abdominal pain.

From the cardiovascular system: peripheral edema.

Other: possible back pain.

Interaction

When used simultaneously with potassium supplements, potassium-sparing diuretics, dietary supplements containing potassium, or potassium salt substitutes, the development of hyperkalemia may occur.

Drugs that affect the RAAS may increase blood urea and creatinine concentrations in patients with bilateral renal artery stenosis or artery stenosis of a solitary kidney. Concomitant use of diuretics and other antihypertensive drugs increases the risk of developing arterial hypotension.

Candesartan increases the concentration of lithium in the blood serum and increases the risk of toxic reactions.

Manufacturer

North Star NAO, Russia